According to Tongbi AI news, Haichang Pharmaceutical announced on June 2, 2026, that the information disclosure obligor Beilu Pharma and Zeng Chunhui have terminated the "Consistent Action Agreement" through an agreement.

Tongbi Finance Tips:

Haichang Pharmaceutical (834402.NQ) had an operating income of 247 million yuan in 2025, with an operating income growth rate of -3.21%. The net profit attributable to the parent company was -9 million yuan, with a net profit growth rate attributable to the parent company of 37.31%. The return on net assets was -4.21%.

The company currently belongs to the healthcare industry, with the main product type being active pharmaceutical ingredients. In the 2025 report, the main composition of sales was contrast agent active pharmaceutical ingredients: 99.32%; sales materials: 0.68%.